Area of research
Neurology · Physiology
Research interest
Research interests include Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments, Voice and Speech Disorders, and Dementia and Cognitive Impairment Research.
Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease
<i>LRRK2</i> -associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization
Occupational Pesticide Exposure in Parkinson’s Disease Related to <i>GBA</i> and <i>LRRK2</i> Variants
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha‐Synuclein Disease
Eleven Years of Change: Disease Progression in Biomarker-Defined Sporadic Parkinson’s Disease
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross‐Sectional Study
Dopamine transporter imaging predicts clinically‐defined <i>α</i>‐synucleinopathy in REM sleep behavior disorder
Comparison of an Online-Only Parkinson’s Disease Research Cohort to Cohorts Assessed In Person
Longitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study
Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
Self-reported physical activity levels and clinical progression in early Parkinson's disease
Cognition among individuals along a spectrum of increased risk for Parkinson’s disease
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
Longitudinal assessment of excessive daytime sleepiness in early Parkinson’s disease
Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease
CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study